Erika Abelleira

Erika Abelleira

Auto-generated profile, based on publicly available information

Erika Abelleira

Division of Endocrinology, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2024 in Thyroid®
Verified
Journal Article
Closed access
FPFabián Pitoia
Fabián Pitoia
EAErika Abelleira
Erika Abelleira
ARAlejandro Román-González
Alejandro Román-González
DDDebora L. S. Danilovic
Debora L. S. Danilovic
RSRafael Selbach Scheffel
Rafael Selbach Scheffel
ICInés Califano
Inés Califano
Background: Surgical resection is not always achievable in thyroid cancer patients. Neoadjuvant therapy is rarely used, but recent trends favor multikinase inhibitors or selective tyrosine kinase inhibitors. These aim to reduce tumor volume, enabling previously unfeasible surgeries. Patients and Methods: Consecutive patients with locally advanced malignant thyroid tumors who received systemic therapies with a neoadjuvant intention were included in this retrospective multicenter case series conducted in five Latin American referral centers. Primary outcomes were pre- versus postneoadjuvant response evaluations using the Response Evaluation Criteria in Solid Tumors, feasibility of surgery, and completeness of resection. Secondary outcomes were mortality and status at the last visit. Results: Twenty-seven patients were included in this analysis. Patients with unresectable differentiated thyroid cancer (DTC) or poorly differentiated thyroid cancer (PDTC) received sorafenib ( n = 6) or lenvatinib ( n = 12), those with medullary thyroid cancer (MTC) were treated with vandetanib ( n = 5) or selpercatinib ( n = 1), and those with anaplastic thyroid cancer (ATC) harboring a BRAF V600E mutation ( n = 3) received dabrafenib and trametinib. The median patient age was 66 years (range 12–82), and 52% of the patients were female. In patients with PTC and PDTC, the median reduction in the diameter of the primary tumor was 25% (range 0–100%) after a median of 6 months of treatment. Surgical intervention was performed in 10 (55%) of the patients. Among these, six patients (60%) achieved R0/R1 resection status. Six patients with MTC had a median reduction in tumor diameter of 24.5% (range 1–49) after a median treatment time of 9.5 months. Only one patient receiving selpercatinib, with a tumoral reduction of 25% could undergo surgery, resulting in an R2 resection due to extensive mediastinal extension. Three patients with ATC showed a median tumor diameter reduction of 42% (range 6.7–50) after a median treatment time of 2 months. Two patients underwent surgical intervention and achieved R1 and R2 resection, respectively. Conclusions: While neoadjuvant therapy achieved tumoral responses, surgical resection was feasible in 55% of DTC, 33% of ATC, and 16% of MTC patients, with R0/R1 resection in 26% of the cohort, underscoring the need for patient selection and further research in this area.

28 November 2023 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
EAErika Abelleira
Erika Abelleira
FJFernando Jerkovich
Fernando Jerkovich

4 August 2020 in Endocrine
Verified
Journal Article
Closed access
PDF file
ASAnabella Smulever
Anabella Smulever
EAErika Abelleira
Erika Abelleira
FBFernanda Bueno
Fernanda Bueno
FPFabián Pitoia
Fabián Pitoia

28 November 2013 in Endocrine
Verified
Journal Article
Closed access
PDF file
PFPitoia Fabián
Pitoia Fabián
AEAbelleira Erika
Abelleira Erika
THTala Hernán
Tala Hernán
BFBueno Fernanda
Bueno Fernanda
UCUrciuoli Carolina
Urciuoli Carolina
CGCross Graciela
Cross Graciela

9 January 2023 in Endocrine
Verified
Journal Article
Closed access
PDF file
FBFernanda Bueno
Fernanda Bueno
ASAnabella Smulever
Anabella Smulever
ICInés Califano
Inés Califano
JGJorgelina Guerra
Jorgelina Guerra
AGAndrés Del Grecco
Andrés Del Grecco
FPFabian Pitoia
Fabian Pitoia

21 May 2024 in Endocrine
Verified
Journal Article
Closed access
PDF file
FJFernando Jerkovich
Fernando Jerkovich
SCSoledad Capalbo
Soledad Capalbo
EAErika Abelleira
Erika Abelleira
FPFabián Pitoia
Fabián Pitoia